Change in timed walk at 6 months (%) e.g. 10‐metre or 6‐minute walk test at 6 months ‐ not measured · people with inclusion body myositis
The review found no eligible studies for this question.
1 finding from 1 review
Change in timed walk at 6 months (%) e.g. 10‐metre or 6‐minute walk test at 6 months ‐ not measured · people with inclusion body myositis
The review found no eligible studies for this question.
1 finding from 1 review
Change in timed walk at 6 months (%) e.g. 10‐metre or 6‐minute walk test at 6 months ‐ not measured · people with inclusion body myositis
The review found no eligible studies for this question.
1 finding from 1 review
Muscle strength · people with inclusion body myositis
2 findings from 1 review
Change in muscle mass at 6 months (%) ‐ not measured · people with inclusion body myositis
The review found no eligible studies for this question.
1 finding from 1 review
Change in handgrip strength at 6 months (%) ‐ not measured · people with inclusion body myositis
The review found no eligible studies for this question.
1 finding from 1 review
Significant adverse events · people with inclusion body myositis
1 finding from 1 review
Muscle strength · people with inclusion body myositis
2 findings from 1 review
Change in muscle mass at 12 months (%) ‐ not measured · people with inclusion body myositis
The review found no eligible studies for this question.
1 finding from 1 review
Change in grip strength · people with inclusion body myositis
1 finding from 1 review
Significant adverse events · people with inclusion body myositis
1 finding from 1 review
Participants able to reduce corticosteroid or IVIg dose by more than 20% · people with CIDP
Methotrexate showed no clear difference in participants able to reduce corticosteroid or IVIg dose by more than… compared with placebo (moderate certainty).
1 finding from 1 review
Change in disability after 26 or more weeks Overall Neuropathy Limitation Scale. Scale from: 0 to 12. · people with CIDP
1 finding from 1 review
Change in disability after 26 or more weeks Amsterdam Linear Disability Scale. Scale from: 0 to 100. · people with CIDP
1 finding from 1 review
Serious adverse events · people with CIDP
Methotrexate showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Muscle strength · people with inclusion body myositis
2 findings from 1 review
Change in muscle mass at 6 months (%) ‐ not measured · people with inclusion body myositis
The review found no eligible studies for this question.
1 finding from 1 review
Change in handgrip strength at 6 months (%) ‐ not measured · people with inclusion body myositis
The review found no eligible studies for this question.
1 finding from 1 review
Significant adverse events · people with inclusion body myositis
Methotrexate probably leads to higher significant adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Short‐term (1 week) percentage change (improvement) in overall speech production · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review